JP7495790B2 - Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス - Google Patents

Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス Download PDF

Info

Publication number
JP7495790B2
JP7495790B2 JP2019552594A JP2019552594A JP7495790B2 JP 7495790 B2 JP7495790 B2 JP 7495790B2 JP 2019552594 A JP2019552594 A JP 2019552594A JP 2019552594 A JP2019552594 A JP 2019552594A JP 7495790 B2 JP7495790 B2 JP 7495790B2
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
ring members
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019552594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515546A (ja
JP2020515546A5 (enExample
Inventor
ハワード、スティーブン
デイビッド コンス、ベンジャミン
デニス、ジェフリー デイビッド セント
メアリー グリフィス－ジョンズ、シャーロット
ダグラス ヒスコック、スティーブン
サラ ホルヴェイ、リアン
リチャード バーンズ、アラン
クーザン、デイビッド
ルイーズ デクスター、ハンナ
フランソワ パラ、ギヨーム
ポール ワッツ、ジョン
ジュウェル、ロバート
アン ストックウェル、ジェニファー
ルイーズ ハースト、キム
アン レマソン、イザベル
ジョン ナッシュ、デイビッド
ダニエル オズボーン、ジェイムス
カリェハ プリード、ジョナス
ポール リチャーズ、ニコラス
マイケル デュマ、アーロン
クリストファー ビショップ、ブライアン
パーリー－ジョンズ、デイビッド
ピーター スコット、ジェレミー
サンダラム シャンマガム、ミーナクシ
リチャード マレンス、ピーター
チャールズ ラスバリー、デイビッド
ジェイムス ディクソン、ダレン
ジェイムス ゴーン、マシュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of JP2020515546A publication Critical patent/JP2020515546A/ja
Publication of JP2020515546A5 publication Critical patent/JP2020515546A5/ja
Application granted granted Critical
Publication of JP7495790B2 publication Critical patent/JP7495790B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019552594A 2017-03-28 2018-03-28 Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス Active JP7495790B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1704965.1A GB201704965D0 (en) 2017-03-28 2017-03-28 Pharmaceutical compounds
GB1704965.1 2017-03-28
PCT/GB2018/050845 WO2018178691A1 (en) 2017-03-28 2018-03-28 Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them

Publications (3)

Publication Number Publication Date
JP2020515546A JP2020515546A (ja) 2020-05-28
JP2020515546A5 JP2020515546A5 (enExample) 2021-05-13
JP7495790B2 true JP7495790B2 (ja) 2024-06-05

Family

ID=58687834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019552594A Active JP7495790B2 (ja) 2017-03-28 2018-03-28 Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス

Country Status (7)

Country Link
US (3) US11603367B2 (enExample)
EP (1) EP3601272A1 (enExample)
JP (1) JP7495790B2 (enExample)
KR (1) KR102673967B1 (enExample)
CN (1) CN110678462B (enExample)
GB (1) GB201704965D0 (enExample)
WO (1) WO2018178691A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
JP2022511437A (ja) * 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス．エー． Ｈｉｖ感染の組み合わせ治療
CN109897069B (zh) * 2019-02-12 2021-08-20 华东师范大学 一种3，3-二取代吲哚啉酮及其衍生物及其合成方法和应用
CN110845288B (zh) * 2019-11-28 2022-07-19 浙江工业大学 一种手性β-氨基醛类化合物的不对称合成方法
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN111057128B (zh) * 2019-12-25 2023-05-16 哈尔滨师范大学 一种含硫的异吲哚酮并环肽衍生物及其制备方法
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
GB202103080D0 (en) * 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CN122555699A (zh) * 2023-11-16 2026-08-11 大冢制药株式会社 制备具有抗癌活性的mdm2-p53相互作用的异吲哚啉酮抑制剂的中间体的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004217591A (ja) 2003-01-16 2004-08-05 Dai Ichi Seiyaku Co Ltd シス選択的フルオロシクロプロパン誘導体の製造方法
US20060264473A1 (en) 2005-05-02 2006-11-23 Vladimir Khazak Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer
JP2011525897A (ja) 2008-06-25 2011-09-29 カンサー リサーチ テクノロジー リミテッド 新しい治療用作用物質
JP2011526260A (ja) 2008-07-03 2011-10-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジニルピリミジン−２−イルアミン誘導体

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH374071A (de) 1959-04-30 1963-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen Isoindolinderivaten
US3466298A (en) 1967-03-14 1969-09-09 American Home Prod Process for the preparation of 2-(2-aminoethyl)isoindolines
US3763178A (en) 1968-09-05 1973-10-02 American Home Prod Imidazolinyl phenyl carbonyl acid addition salts and related compounds
CY787A (en) 1970-02-12 1976-06-01 American Home Prod Novel phtalimidine compounds
AR203996A1 (es) 1972-03-16 1975-11-12 Rhone Poulenc Sa Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1
FR2217000B1 (enExample) 1973-02-08 1976-04-09 Rhone Poulenc Ind
GB1601701A (en) 1977-07-22 1981-11-04 Delmar Chem Production of heterocyclic benzamide compounds
US4200759A (en) 1978-07-20 1980-04-29 Delmar Chemicals, Limited Preparation of imidazo[2,1-a]isoindole compounds
US4244966A (en) 1979-09-24 1981-01-13 American Home Products Corporation 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives
US4312809A (en) 1980-10-31 1982-01-26 E. R. Squibb & Sons, Inc. Lactam derivatives of mercaptoacylamino acids
US4331600A (en) 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
FR2533563A1 (fr) 1982-09-23 1984-03-30 Adir Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
HU212435B (en) 1990-06-07 1996-06-28 Sandoz Ag Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients.
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
DE19807423A1 (de) 1998-02-21 1999-08-26 Hoechst Marion Roussel De Gmbh Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln
EP1199306B1 (en) 1999-07-26 2005-12-07 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
AU1466001A (en) 1999-11-05 2001-05-14 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
KR100650966B1 (ko) 2001-12-18 2006-11-30 에프. 호프만-라 로슈 아게 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
CN100548980C (zh) 2002-11-26 2009-10-14 丸石制药株式会社 异吲哚啉衍生物
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2005255660A (ja) 2004-03-10 2005-09-22 Katsuhiko Tomooka 多官能基を有するラクタム類とその製法
JPWO2005095341A1 (ja) 2004-03-30 2007-08-16 協和醗酵工業株式会社 含窒素複素環化合物
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
AU2006216780B8 (en) 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JPWO2008047831A1 (ja) 2006-10-17 2010-02-25 協和発酵キリン株式会社 Ｊａｋ阻害剤
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CA2734363C (en) 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
CN104876938A (zh) 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
TR201807311T4 (tr) 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
EP2721008B1 (en) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
KR101401705B1 (ko) 2012-01-31 2014-06-27 울산대학교 산학협력단 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
PT2914254T (pt) 2012-10-30 2020-04-02 Mei Pharma Inc Terapias de combinação para tratar cancros quimiorresistentes
CN105025884B (zh) 2013-03-01 2019-08-20 阿斯泰克斯制药公司 药物组合
AU2014286237B2 (en) 2013-07-03 2020-08-20 F. Hoffmann-La Roche Ag mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
US20160333419A1 (en) 2014-01-14 2016-11-17 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
AU2015247646B2 (en) 2014-04-17 2019-06-06 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
JP2017532959A (ja) 2014-10-09 2017-11-09 第一三共株式会社 Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
EP3206697A2 (en) 2014-10-17 2017-08-23 Biomirna Holdings Ltd. Lung cancer diagnostics and therapeutics with mir-660
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
WO2017068412A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US11339448B2 (en) 2018-07-27 2022-05-24 Ottawa Hospital Research Institute Treatment of acute myeloid leukemia
EP3814525A4 (en) 2019-02-24 2022-04-13 Ascentage Pharma (Suzhou) Co., Ltd. TREATMENT METHODS AND BIOMARKERS FOR MDM2 INHIBITORS
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004217591A (ja) 2003-01-16 2004-08-05 Dai Ichi Seiyaku Co Ltd シス選択的フルオロシクロプロパン誘導体の製造方法
US20060264473A1 (en) 2005-05-02 2006-11-23 Vladimir Khazak Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer
JP2011525897A (ja) 2008-06-25 2011-09-29 カンサー リサーチ テクノロジー リミテッド 新しい治療用作用物質
JP2011526260A (ja) 2008-07-03 2011-10-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジニルピリミジン−２−イルアミン誘導体

Also Published As

Publication number Publication date
US11603367B2 (en) 2023-03-14
US20210101887A1 (en) 2021-04-08
GB201704965D0 (en) 2017-05-10
CN110678462A (zh) 2020-01-10
US20250074900A1 (en) 2025-03-06
KR20190133190A (ko) 2019-12-02
KR102673967B1 (ko) 2024-06-12
EP3601272A1 (en) 2020-02-05
CN110678462B (zh) 2024-10-29
US12077526B2 (en) 2024-09-03
WO2018178691A1 (en) 2018-10-04
JP2020515546A (ja) 2020-05-28
US20230278989A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
JP7566806B2 (ja) 抗がん活性を有するｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤
US12077526B2 (en) Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them
KR102743663B1 (ko) 항암 활성을 갖는 mdm2-p53 상호작용의 아이소인돌리논 저해제
HK40082646A (en) Intermediates of isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
HK40088238A (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
RU2794333C1 (ru) Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью
RU2797295C1 (ru) Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью
HK1250715B (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240524

R150 Certificate of patent or registration of utility model

Ref document number: 7495790

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150